Background
Brian Rifkin
Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

Potassium Rollercoaster Heartbreak
Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Background
Brian Rifkin
The Ondansetron Ballet: Torsades de Pointes

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

The Ondansetron Ballet: Torsades de Pointes
Background
Cristina Adriana Popa
Re”FINE”ing the role of non steroidal MRAs in ...

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Background
Cristina Adriana Popa
Playing It Safe: Can Felzartamab Fill the Gap ...

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?

dialysis

TenXeetNephJC? TenPostNephJC? It's HDF and CONVINCE anyway.

Huge trial on our core work, catch-up here

Checking in on MyTEMP - #TenTweetNephJC

The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.

The Roxadustat Chronicles: A Two-Article NephJC

The Roxadustat Chronicles: A Two-Article NephJC

The HIF inhibitor trials were announced almost a year and half ago at KidneyWk 2019. We are finally seeing the trials get published. Here are the first two, a sub-group analysis of three dialysis studies focused on incident dialysis patients and a placebo controlled pre-dialysis study.